The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis

Kang, Kwi Young; Lee, Kwan Yong; Kwok, Seung‐Ki; Park, Kyung-Soo; Hong, Yeon Sik; Kim, Ho-Youn; Park, Sung-Hwan

doi:10.1016/j.jbspin.2010.05.010

Cited by 32 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multiple inflammatory cytokines, chemokines, and immune cell growth factors activate osteoclasts, leading to low BMD (2). Patients with AS have an increased risk of osteoporosis, with a reported prevalence ranging from 13% to 37% (3,4). Low BMD in the spine and hips is characteristic of patients with long-standing and severe AS, and recent reports suggest early-stage spondyloarthropathies also show loss of bone mass (5).…”

mentioning

confidence: 99%

Assessment of fracture risk in patients with axial spondyloarthritis: a case–control study using the fifth Korean National Health and Nutrition Examination Survey (KNHANES V)

et al. 2015

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Assessment of fracture risk in patients with axial spondyloarthritis: a case–control study using the fifth Korean National Health and Nutrition Examination Survey (KNHANES V)

et al. 2015

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

show abstract

“…Because CRP levels and ESRs reflect inflammatory activity in AS, our results also indirectly support the theory that inflammatory activity may alter bone metabolism and lead to a low BMD [8][9][10].Furthermore, multivariate binary logistic analysis revealed that a higher BASMI was independently associated with a low BMD. Indeed, other studies have also found that low physical activity in AS could be correlated with a low BMD [3,7].…”

Section: Discussionmentioning

confidence: 89%

“…Various factors, such as [3,[7][8][9]. However, the pathogenesis of low BMD in AS is controversial, and the mechanisms are unclear.…”

Section: Discussionmentioning

confidence: 99%

“…Various factors, such as male gender, treatment, hormone disorders, AS duration, and decreased physical mobility, may contribute to the development of Yanfeng Wu and Huiyong Shen have contributed equally to this work. OP in AS [3,7]. Several studies have shown that significant low bone mineral density (BMD) in AS is strongly associated with elevated levels of inflammatory biochemical markers, such as C-reactive protein (CRP), the erythrocyte sedimentation rate (ESR), interleukin-6, and tumor necrosis factor-α [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Relationship of Bone Mineral Density to Oxidant/Antioxidant Status and Inflammatory and Bone Turnover Markers in a Multicenter Cross-Sectional Study of Young Men with Ankylosing Spondylitis

et al. 2015

View full text Add to dashboard Cite

Low bone mineral density (BMD) is an important complication of ankylosing spondylitis (AS) that seriously affects men and their quality of life, even in young patients. However, the relationships among redox; levels of bone turnover markers (BTMs), inflammatory markers and disease activity; and low BMD in AS require clarification. We recruited 102 men aged 30-39 year with AS and 102 healthy, sex- and age-matched controls for this cross-sectional study. The subjects were analyzed for lumbar spine and femoral neck BMD by dual-energy X-ray absorptiometry. Significantly lower BMD and corresponding T-scores were observed in the AS patients compared with the controls (P < 0.05). The oxidant biomarker and antioxidant levels were significantly (P < 0.05) higher and lower, respectively, in the AS subjects compared with the controls, and the bone resorption and inflammatory marker levels were higher (P < 0.05). In subgroup analyses, the patients with osteoporosis or active disease had the highest levels of oxidant biomarkers (P < 0.05). Furthermore, the BMD T-scores in AS were found to be negatively correlated with oxidative status (P < 0.05). Multivariate binary logistic analysis showed that low BMD in the AS patients was associated with higher levels of advanced oxidation protein products, malondialdehyde and C-terminal telopeptide of type I collagen; lower levels of glutathione peroxidase; and higher scores of a bath ankylosing spondylitis metrology index. In conclusion, imbalanced redox was independently associated with low BMD in young men with AS and may play an important role in the pathogenesis of AS-related low BMD.

show abstract

“…The anti-inflammatory effect of etanercept in patients with RA is widely accepted (4)(5)(6)(7). Although a previous study indicated that inhibiting inflammation in RA is insufficient to inhibit bone destruction (8), another study showed that TNF-α blockers directly mitigate osteoporosis (9). It was also suggested that TNF-α inhibitors prevent resorption of the bone adjacent to the joints (10).…”

Section: Introductionmentioning

confidence: 99%

Induced production of anti-etanercept antibody in collagen-induced arthritis

Kim

Jung

et al. 2014

Molecular Medicine Reports

Self Cite

View full text Add to dashboard Cite

Abstract. Etanercept is a widespread biological drug for the treatment of rheumatoid arthritis, which inhibits tumor necrosis factor-α (TNF-α). Recently, the presence of antibodies targeting TNF-α inhibitors such as infliximab and adalimumab, was reported. However, few reports have studied etanercept in a mouse model of arthritis. We investigated the induction of anti-etanercept antibody production, along with the antibody's potential interfering effects on the biological function of etanercept, in mice with collagen-induced arthritis (CIA). CIA mice received an intraperitoneal injection of etanercept (25, 100 or 400 µg per mouse). The degree of inflammation and cartilage erosion was evaluated, and the number of osteoclasts in the ankle joints was assessed by TRAP staining. The level of pro-inflammatory cytokines in the serum was measured. To analyze the anti-osteoporotic effect of etanercept, microfocal computed tomography analyses of femurs and tibias were performed. Etanercept treatment decreased both the incidence and severity of arthritis in a dose-dependent manner, except for the highest dose of 400 µg. The mice that were treated with 25 and 100 µg etanercept showed an improvement in inflammation, cartilage damage, and even bone loss. However, mice treated with 400 µg etanercept showed no significant improvement in any of the tested parameters. Using a customized enzyme-linked immunosorbent assay (ELISA), the presence of the anti-etanercept antibody was detected in the serum in this treatment-refractory group. The therapeutic effect of etanercept was reduced in the CIA mice that developed the anti-etanercept antibody. In conclusion, the production of an anti-etanercept antibody can be induced in CIA mice, and this antibody can considerably reduce the anti-arthritic and anti-osteoporotic effects of etanercept.

show abstract

The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis

Cited by 32 publications

References 29 publications

Assessment of fracture risk in patients with axial spondyloarthritis: a case–control study using the fifth Korean National Health and Nutrition Examination Survey (KNHANES V)

Assessment of fracture risk in patients with axial spondyloarthritis: a case–control study using the fifth Korean National Health and Nutrition Examination Survey (KNHANES V)

The Relationship of Bone Mineral Density to Oxidant/Antioxidant Status and Inflammatory and Bone Turnover Markers in a Multicenter Cross-Sectional Study of Young Men with Ankylosing Spondylitis

Induced production of anti-etanercept antibody in collagen-induced arthritis

Contact Info

Product

Resources

About